Todos Med Ltd (TOMDF)

[redspeed]

Biotechs going out of business isn't new except to the stock analyst. They are high risk and high reward as I said many times. I posted a link to a ton over the last 10 years. Here's a different one. Odds are great if you bet against any microcap biotech you will be right most of the time.

Biotech bankruptcies hit 10-year peak in 2023 - Feb 12, 2024
https://www.fiercebiotech.com/special-reports/biotech-bankruptcies-break-10-year-record-2023

The list for 2024 will included companies like TOMDF, IBIO and others. The later that CEO was raking in $5M of comp as an example, all the while the stock analyst was licking his boots and road the stock down from $2750 to a buck through 3 reverse splits.

I cycled most of my money out of tech at the right time and back in to take a nice AI ride. One would be foolish to bet their life savings in stocks like TOMDF, IBIO, etc. but you'd be surprised at least one person did.

[velcro]

Unfortunately, Gerald Commissiong is feeling no guilt. He blamed creditors for shutting down his company --seems like a good reason if you can't pay your bills.
During the Covid heighth I can still see GC on Fox Business with Stuart Varney. It generated investors who all lost their money.

[redspeed]

" It's apparent the stock analyst can't stop thinking about it." –Red

"Nothing is more wretched than the mind of a man conscious of guilt." –Plautus.

"No work or love will flourish out of guilt, fear, or hollowness of heart, just as no valid plans for the future can be made by those who have no capacity for living now." –Alan Watts

Obviously fears the SEC will crack down for the fraud to Todos investors. May have peeps on some other tickers pile on to the lawsuits as well.

Do prisoners get to eat pizza and/or have access to TolloVID Gromwell Root as a topping?
While federal prisoners can't order Dominoes pizza or have anything they might want, they have what they need and they all get by with what's provided, even if the food quality and quantity can sometimes leave something to be desired.

[JPetroInc]

bring it Mista Redspudda

your thesis holds no water whatsoever - and is patently false, inaccurate and inactionable

and false claims such as these could prolly be held liable in a counter suit scenario

any TOMDF Boiler Room Pumper Boy ring leader is a fake phony shill tout and dolt

everything else is - well you know - the same old Blah Blah Blah Blah Blah...!



anyone can speak to the hand puppet anytime - if so inclined...!

can't wait for the outing brah...!



MOO bad brains

[theswordman]

Looks like the redspeed sputter must be on to something with the legal issues / jwpetro stock analysts and their fraudulent statements against the former Todos CEO and their fraudulent statements about no DRs using OTC products and no Drs treating patients using Tollovid. Uncle Jedwp done loaded up the truck and run back to the hills.

[JPetroInc]

to all the TOMDF Boiler Room Pumper Boys:

lets hear a little chatter out there...



MOO told you so

[JPetroInc]

***** here's 5 Stars *****

for turning out the TOMDF lights ...



SMH - what a lonely job I tell ya...!

MOO Moshe'

[theswordman]

BNO News @BNOFeed
Weekly U.S. COVID update:

- New cases: 85,366 est.
- Average: 113,856 (-22K)
- States reporting: 50/50
- In hospital: 10,458 (-1K)
- In ICU: 1,402 (+7)
- New deaths: 1,202
- Average: 1,322 (-112)

BNO ANALYSIS
This is the 29th week in a row with more than 1,000 new COVID deaths, or nearly 48,000 deaths during the same period.
So far this year, more than 2.8 million cases of COVID have been reported in the U.S., causing 243,599 hospitalizations and 24,406 deaths.

[JPetroInc]

who says it was pretend - you - really...?

"Anyone that calls into a investor call like the ones the CEO of this company held and pretends to be a stock analyst pretends to be a stock analyst should pay of heavy penalty and/or go to jail for fraud."

you or you're ilk need to contact Precision1 - but you won't or can't - because they're outta business

so you'll just have to settle for the truth - which is the AMBS CC intake rep recorded it wrong

FYI here is the 'official' AMBS Stock Analyst list sporto:



anything else is subject to one's own interpretation

and for some - that could be a bad thing...!



SMH - TOMDF printing $0.000001 and TolloUp ButterCup 9 Horsies are DOA & DISSOLVED

MOO bad brains

[theswordman]

SUN NITE--BNO
BNO News @BNOFeed
Weekly U.S. COVID update:

- New cases: 97,352 est.
- Average: 136,429 (-22K)
- States reporting: 50/50
- In hospital: 11,785 (-1K)
- In ICU: 1,395 (-208)
- New deaths: 1,116
- Average: 1,434 (-114)
BNO ANALYSIS--This is the 28th week in a row with more than 1,000 new COVID deaths, or nearly 47,000 deaths during the same period.
So far this year, nearly 2.8 million cases of COVID have been reported in the U.S., causing 234,000 hospitalizations and 23,204 deaths.

[redspeed]

Congratulations⭐⭐⭐⭐⭐ Star post brah. And yet another one resurrected from the dead.

Obvious why someone so hideous of heinous crimes would try to hide a pitch perfect post...

about the CEO of AMBS and Todos unless...

“Only those afraid of the truth seek to silence debate, intimidate those with whom they disagree, or slander their ideological counterparts. Those who know they are right have no reason to stifle debate because they realize that all opposing arguments will ultimately be overcome by fact."

Facts are...

Anyone that calls into a investor call like the ones the CEO of this company held and pretends to be a stock analyst should pay of heavy penalty and/or go to jail for fraud.

There I said it again.

Did I stutter or stammer?

Ten years wasted...

So sad.

[LUCKYBUTT]

Nice post

[redspeed]

Anyone that calls into a investor call like the ones the CEO of this company held and pretends to be a stock analyst should pay of heavy penalty and/or go to jail for fraud.

[JPetroInc]

its simple - whatever I say or try to explain ...

you will obfuscate and create false narratives around it

that's just how you, Mista Redspudda and Joey-the-Forkit-Bolo operate in the Back Office Boiler Room

and the fact that you were all warned - by me a number of others ...

who knew that Gerald Commissiong is a sham CEO and TOMDF was going to go belly-up

just like he did with AMBS - broke - insolvent - OTC delinquent, dark & non-reporting

in essence, here's all that really matters to YOU sport or anybody else in Tolloup Buttercup Todosville

Todos Medical - permanently dissolved & out-of-business:



TOMDF Printing $0.000001 and zero volume:



but all is not lost the S wordman

because here is one last opportunity for you to "sell me this pen"



SMH - sad but true

MOO slow brains

[theswordman]

No sir--you NEVER tell us how your name is listed TWICE--2 different times. As a stock analyst--you show the companies that have analysts listed as covering the stock. You deflect dodge defer. Sorta your life story but hey; you do you

And be sure to add movie star pix--and talk about Gerald--but NEVER ever be honest

Good Job JWP

[JPetroInc]

yo Swordie it’s been answered

more than a dozen times

but no matter how many times it’s been answered is meaningless…

cause you are in denial - or refuse to listen

but hey, good luck with your TOMDF holdings sporto

you, Redspudda and Joey-the-Forkit-Bolo are going to need it…

printing $0.000001 - Tollo-up ButterCup pulled from all store shelves…!

SMH - sad but true

MOO slow brains

[JoeForkeyBolo]

The question that is never answered is this:

Why provide your company name again on the second investor call, if you claim that caused the error on the first investor call?

A. I forgot about the first call where I was presented as an analyst.
B. They made the mistake AGAIN on the second call. Gerald should have corrected it. It's all his fault.
C. I wanted to be presented as an analyst again. I liked the feeling of importance from the first call.

The facts support answer C. The first call could have been a mistake. The second call definitely was not a mistake. It was intentional because the caller already knew how he would be presented on the call if he provided his company name in lieu of informing the host he was a private investor, as other private investors had done.

Here's an article I found in The Wall Street Journal. Does this sound like someone you've heard on an investor earnings call? On perhaps multiple calls?

https://www.wsj.com/articles/SB120301945499169247

Analyze This: Hoaxer Haunts Earnings Calls
By Betsy McKay
Feb. 16, 2008

Some big companies have had a surprise during their earnings conference calls this quarter -- and it has nothing to do with the weak economy.

At least seven times just the past three weeks, a mystery caller has cleverly insinuated himself into the normally well-manicured ritual of the quarterly calls. As top executives of publicly traded companies respond to securities analysts' questions about their balance sheets, he impersonates a well-known analyst to get called upon. Then, usually declaring himself to be "Joe Herrick of Gutterman Research," he launches into his own version of analyst-speak.

"Congratulations on the solid numbers -- you always seem to come through in challenging times," he said to Leo Kiely, president and chief executive officer of Molson Coors Brewing Co., on Feb. 12, convincingly parroting the obsequious banter common to the calls. "Can you provide some more color as to what you are doing for your supply chain initiatives to reduce manufacturing costs per hectoliter, as you originally promised $150 million in synergy or savings to decrease working capital?"

Analysts say the caller's questions, though credibly phrased, are too off-target for a real analyst. It's more like "consultant-speak," says a disdainful Bryan Spillane, a Banc of America Securities analyst, a victim of one of Mr. Herrick's impersonations. Analysts deal with often-wonky financial details, but "savings per hectoliter" rarely comes up.

But many CEO's have had more trouble telling the difference. Most have gamely tried to answer the questions. Mr. Kiely and two other Molson executives stuck politely with the caller through three detailed follow-ups. Timothy Wolf, the company's global chief financial officer, closed by telling him, "We think we will have some more positive encouraging things to share with you next month in New York," according to a transcript of the call. A Molson spokesman said that to him the caller sounded legitimate at the time.

Executives at PepsiCo Inc., Dean Foods Co., Newell Rubbermaid Inc. and others have had similar experiences since around mid-January. The caller first gives a familiar name to conference-call operators to earn a turn speaking in the calls -- in which dozens of listeners can dial in, but typically just a handful of analysts known to the company get to ask questions. When he's called upon, he corrects the conference-call operator and identifies himself as Joe Herrick (or Harrick in one transcript). He says he is from a firm called Gutterman Research, or in one case Vladimir Research, according to transcripts provided by Thomson Financial.

Analysts and companies contacted about the caller are stymied as to who he could be. Searches using several potential spellings failed to turn up the name or firms on a Financial Industry Regulatory Authority database of registered securities firms and brokers, or on the Securities and Exchange Commission's Investment Adviser Public Disclosure Web site. A Google search found transcripts of several earnings conference calls in which Mr. Herrick has participated. A New York City telephone number used by the caller to phone into one conference call, and obtained by The Wall Street Journal, disconnects immediately when dialed. Of course, Mr. Herrick could still pop up and prove he is for real.

Meanwhile, annoyed executives and analysts are wondering why someone would want to play a game with dry business calls that normally follow a tightly controlled formula -- unless the game is the whole point. They can't figure out how the caller is getting any benefit from so closely mimicking them. "If he was spoofing I would hope he'd be funnier," says Bill Schmitz, an analyst at Deutsche Bank Securities.

Word of the impersonations has been slow to spread. Mr. Schmitz outed the caller on Newell Rubbermaid's Jan. 31 call, having already heard him several times going back to mid-January. Yet the caller was still using other names to get access as late as Thursday, in a call with Jarden Corp. Yesterday, a caller gave a different name and firm, Mindful Capital Investments, on a call with Hormel Foods Corp., but sounded as if he were reading from a similar script. Mr. Herrick's questions are usually narrowly focused on details of a company's results from well-known cost-savings techniques such as "lean management" and Six Sigma, or else supply-chain issues. They're virtually the same on each call, and he often follows up aggressively.

In the Newell Rubbermaid call, Mr. Herrick asked the company's president and chief executive, Mark Ketchum, to outline his "top initiatives regarding lean manufacturing" and Six Sigma. Afterward, Mr. Schmitz came on and warned the executives.

"Hey guys. First, this guy, Joe Gutterman [sic], every conference call this quarter, he logs on as somebody's name and asks these crazy efficiency questions," he said. "So going forward keep in mind you should just disconnect him when he dials in. This is like the sixth call in a row he's done that. It's really annoying." Mr. Schmitz speculates that Mr. Herrick is "some minion" at a consulting firm trying to do clandestine research on companies' use of Six Sigma techniques.

"Our quarterly earnings calls are key opportunities to us to interact with the investment community and to explain our results," says a Newell Rubbermaid spokesman, David Doolittle. "Anyone who would come on the call and use some of that time unproductively is disruptive."

Some companies are now on the alert. Coca-Cola Co. executives listen to the calls of PepsiCo, and they heard Mr. Herrick bombard PepsiCo Chairman and CEO Indra Nooyi on her Feb. 7 call. So Coke gave select analysts a secret password to use to ask questions during its own call Wednesday -- "Diet Coke" -- according to analysts who participated in the call. A Coke spokesman wouldn't comment on steps the company took beyond saying it was "prepared for this and had a contingency plan in place."

Coke's caution was evident when Banc of America's Mr. Spillane, the earlier impersonation victim, posed a detailed question about how much of the company's currency-neutral operating profit growth was organic rather than coming from acquisitions or cost savings. "We hesitated on you for a minute because as we take these questions we are just trying to make sure that in fact you are who you say you are," Coke's chief financial officer, Gary Fayard, said before launching into an answer. "I am the real deal," Mr. Spillane replied.

PepsiCo, not to be outdone by Coke, says it's tightening its screening process to ensure callers are legitimate. "If we find out differently they will be cut off immediately," says a PepsiCo spokesman.

While competition to get into the question queue is keen for a call hosted by PepsiCo or other large corporation, because many analysts and investors dial in, getting to ask a question on a smaller company's call is easy. That makes some of Mr. Herrick's impersonations even stranger, says Bill Pfund, vice president of investor relations for WMS Industries Inc., a slot machine maker in Waukegan, Ill. "It's an open forum," he says. "If you have a question, just come in under your name." It's also unusual for someone to participate in calls for such a broad swath of industries, from beverages to slot machines.

In WMS's conference call Feb. 6, Mr. Herrick asked president and CEO Brian Gamache about "operational improvement initiatives revolving around lean and Six Sigma," according to a transcript. "You always [seem] to come through in a very challenging time," he made sure to say in conference-call style, applauding the company's "good results."

Mr. Herrick's continued appearance on conference calls is becoming a running joke in the analyst community, says John Faucher, a beverage analyst with J.P. Morgan, whose place Mr. Herrick took in the PepsiCo call. Mr. Faucher, who has been keeping tabs on the caller by instant messaging with clients, took a sort of revenge by spoofing Mr. Herrick in a research note following Coke's earnings call on Wednesday. "The only real disappointment on the Coke call was not hearing about their 6 sigma and RONA policies," he wrote.

Mr. Herrick is giving analysts another reason to look forward to a big conference many of them plan to attend in Boca Raton, Fla. next week. Says Mr. Faucher: "One of the big questions is, will Joe Herrick from Gutterman Research show up?"

[1maga1]

Holy cow now that’s some DD

[theswordman]

Notice that is NOT a answer to the question that was asked.

Notice there is NEVER a answer from the person that their name is on the document/link. You know the person that tries to claim they were not a stock analyst. That claims their name is NOT on that document. Just always dodge deflect defer. Sorta sad--just lil movie star photos

I wonder why??

Oh my

[JPetroInc]

yip Velcro precisely right

however the Boiler Room Pumper Boys Redspudda, JoeyForkitBolo and Swordie ...

would rather have everyone focus on everything other than the AMBS ot TOMDF CEO failure

who they were pumping like a tire pressure filling station all along

and thats been the moral of the story here forever

SMH sad but true...!

Tollovid Snake Oil - now outta business folks...



MOO shills touts & dolts

[velcro]

This was 2013. GC postured on increasing shareholder value by market adjustments such as reverse split.

[redspeed]

One of the two of these analyst already served his time in JAIL that would get on the CEO calls.

The second one has been exposed for getting on investors calls pretending to be a stock analyst ON MULTIPLE CALLS. He even has a bunch of burner email address from yahoo, AOL, MSN, etc. but no real company email. Apparently that is common scam when you look at your spam folder.

[theswordman]

Notice you NEVER address this link--that shows your name

http://content.stockpr.com/amarantus/media/782786d417b8894297ed7f45f31a9e42.pdf

Oh my--danile is not just a river

[redspeed]

Didn't the stock analyst claim he was gonna have that company take down the transcript? What a liar.

I bet they laughed their arses off when they got the call and told him to go pound sand, as they made no mistake he continues to claim.

A steep penalty and/or jail time for fraudulently pretending to be a stock analyst with no license would be in order, but we'll let the courts decide.

Do they serve pizza in jail?

[redspeed]

Wow, that is definite proof and should be sent to the SEC ASAP. Crimes should not go unpunished.

If any investors were a victim of these alleged heinous crimes, they are well within their right to file a civil lawsuit for damages. Between AMBS and TOMDF, the liability is in the millions.

[JPetroInc]

yo Joey - I know understanding this mater is like

maybe like understanding Differential Equations, Determinate & Indeterminate Structures or Calculus 3

but here's the bottom line Sporto

"Your list of analysts covering Amarantus Biosciences is incomplete."

the list in question says it was issued by Amarantus Bio under the failed CEO Gerald Commissiong



any further issues you, and your TOMDF buds Swordie and Redspudda

are free to address it with the intake rep at Precision IR Group at ph. 804-327-3400, as follows:



meanwhile back at the 3.3-BIL OS TOMDF printing press

all TOMDF stock certificates have transformed themselves into worthless toilet paper - eh JOEY...?



it also looks like TOMDF shareprice $0.000001 ain't looking so good for TOMDF SH's - eh JOEY

not with these worthless toilet paper certificates in ones TOMDF Fidelity account holdings:



uh oh, so much for the 'truth be known'

but hey, what's a few "dollas" among friends - eh JOEY



MOO shill tout dolt

[JoeForkeyBolo]

Your list of analysts covering Amarantus Biosciences is incomplete. After listening to multiple Amarantus conference calls provided to me by former AMBS investors (thanks again for your support), the following analysts were identified on the calls. You will note that there were 4 analysts on the calls NOT on the lists of analysts you provided. They are identified in red. Par for the course with inadequate DD on your part. I would be happy to post the audio files from the conference calls if necessary.

I also included your name for the calls where you presented yourself as an analyst. All other callers who were private investors identified themselves as such. One has to wonder why you didn't identify yourself as a private investor. One could understand the mistake on the November 2013 call, where you posted you didn't know they would announce your company name on the call, or identify you as an analyst. This might have been your first investor conference call, but the call was posted on the AMBS board and the transcript of the call made available that listed you as an analyst. Yeah, okay, their mistake, right?

But on the September 2014 call you once again you identified yourself with your company name, knowing they would identify you as an analyst on the call. Why create the same "error" again unless it was intentional—you wanted to be identified as an analyst. Mistake the first time? Maybe. Mistake the second time? No one is buying that. The SEC is not likely to see it as a mistake repeated a second time one year later. I think they'll come to the same conclusion reached on this board.

April 2013 AMBS Conference Call
Jason Napodano — Zacks Investment Research
Matthew Margolis — OneMedPlace Global Investments

November 2013 AMBS Conference Call
Jason Napodano — Zacks Investment Research
John Petrosino — JWP Incorporated

April 2014 AMBS Conference Call
Jason Napodano — Zacks Investment Research
Nick Cooper — Edison Investment Research
Jeffrey Kraws — Crystal Research Associates

September 2014 AMBS Conference Call
Jason Napodano — Zacks Investment Research
John Petrosino — JWP Incorporated
Jolene Furdek — Edison Investment Research

The fact your name doesn't appear on your list of certified analysts means nothing. The four analysts I identified from the calls (but not on your list) are also FINRA licensed and were clearly interested in Amarantus. More evidence for the SEC looking into this matter. I would be concerned if I were in your shoes.

One other point. From listening to these calls and the numerous Amarantus corporate advisors, it was clear to me this company wasn't the scam you claim. They were very engaging and extremely knowledgeable in their respective fields of expertise. CEO Gerald Commissiong might have made bad choices in funding the company, but it was clear he assembled a top-notch team. I believe he was also on the right track with Todos Medical. But small companies face a lot of hurdles and neither company survived. I lost money in Todos and I own the decision to invest. I don't put all the blame on the CEO, as some do. Anyone who decides to invest 6-figures-plus in a penny stock company with zero revenue has only themselves to blame for that decision. They can either OWN IT, or act like a CRYBABY and blame others.

[redspeed]

That document says it all. SOMEBODY was pretending to be a stock analyst multiple times on multiple calls. Wonder how many years in jail would be the penalty if convicted for those heinous crimes? I guess the stock analyst could plead he was a blithering fool and throw himself at the mercy of the court.

btw: Do you think they allow harlequin romance novels or how to buy stock books in prison?

[theswordman]

So you are saying this document is invisible??

Oh my

http://content.stockpr.com/amarantus/media/782786d417b8894297ed7f45f31a9e42.pdf

Reads like Joe Forks got it 100% CORRECT

[JPetroInc]

JoeForkitBolos gets it wrong again folks

not sure where these false narratives & fake posts originated from

but it sure seems apparent who they are being disseminated by...!

FYI JOEY - here's the certified "AMBS Stock Analyst List"

3 analysts who are all FINRA licensed & approved to represent AMBS

just lookie here folks - no JWP, Inc firm on it whatsoever:



and do you know why JWP, Inc is not on the approved FINRA stock analyst list for AMBS...?

because JWP, Inc is not a stock analyst firm - never was - never will be - eh JOEY...!

yeah, and those dissolved insolvent liquidated TOMDF shares are'nt looking too good these daze either

not while printing $0.000001 and being permanently "out-of-business"



so lets find out - who do TOMDF shareholders love - maybe this guy - eh JOEY:



SMH folks - can't make this shite up

sell me this pen - lolzzz



MOO shills & touts

[JoeForkeyBolo]

That explains why the Amarantus shareholder from JWP Inc. didn't recall the fact he had participated in two conference calls posing as a stock analyst. How many times did he contract Covid? Too bad he wasn't taking Tollovid.

[theswordman]

SUN NITE--BNO Covid Update
BNO News @BNOFeed
Weekly U.S. COVID update:

- New cases: 126,117 est.
- Average: 158,945 (-23K)
- States reporting: 50/50
- In hospital: 13,298 (-1K)
- In ICU: 1,603 (-242)
- New deaths: 1,311
- Average: 1,548 (-124)

BNO Analysis:
This is the 27th week in a row with more than 1,000 new COVID deaths, or nearly 46,000 deaths during the same period.

So far this year, nearly 2.7 million cases of COVID have been reported in the U.S., causing 223,000 hospitalizations and more than 22,000 deaths.

[redspeed]

I knew something wasn't right...

New Evidence Suggests Long COVID Could Be a Brain Injury
February 08, 2024

Researchers found that 351 patients hospitalized with severe COVID-19 had evidence of a long-term brain injury a year after contracting the SARS-CoV-2 virus. The findings were based on a series of cognitive tests, self-reported symptoms, brain scans, and biomarkers.

https://www.medscape.com/viewarticle/new-evidence-suggests-long-covid-could-be-brain-injury-2024a10002v0?form=fpf

Holy Sh-t...

Brain Deficits Equal to 20 Years of Brain Aging

So let's say one is in their late sixties. If they were hospitalized with severe COVID-19, that would be like late 80's?

Wow. Glad I have a lot of 3CL Protease Inhibitor in my house. Who wants to end up in the hospital sucking O2 and end up with a Brain Deficits Equal to 20 Years of Brain Aging.

TolloVID will surprise boi

[JPetroInc]

what shocking is the fact that you have an inexperienced manipulative twice failed hack CEO

broadcasting intellectual prowess stating he's a Stanford "Financial Engineer" who understands finance

yet ran TOMDF to 3.3-BIL. OS Shares, and used toxic death spiral convertibles

employing the Astoria Queens financial mafia to fund themselves

and put out PR after PR about just how great TOMDF and Tollovid Chinese gromwell root extract was

and how Todos Medical was saving the world from COVID and was developing an ANTI-COVID pill



then switched to saving LH-COVID sufferers when the pandemic was declared over by the US-NIH

TOMDF also spent (+/-) $138-Mil. in aprox 5 yr's and would up dissolved

with unaudited books and an OTC Dark or Defunct Non-reporting status

just lookie here 3.3-Bil. OS shares - yes that's BILLION SHARES folks for starters:



now peruse the timing and dates of TOMDF's PR releases

and hold that up against TOMDF's 5 Year TA Chart

then tell me what you see...?



TOMDF Sham Exposed in PR Chronological Order

Todos Medical Announces Insolvency Proceedings in Israel
Dec 22, 2023 5:28pm EST

Todos Medical Provides Corporate Update: Retooling to Focus on Long COVID Epidemic
Sep 26, 2023 11:01am EDT

Todos Announces Notice of Allowance From USPTO for Patent Application Covering Use of Compositions In Tollovid™ and Tollovir™ Ingredients
Aug 30, 2023 8:19am EDT

Todos Medical Enters Into Letter of Intent for Provista Diagnostics to License PCR-based Sepsis Diagnostic Test AcuSept LDT Rights From Acumen Diagnostics
Mar. 28, 2023

Todos Medical Begins Trading on the OTC Pink Marketplace
Mar. 27, 2023

Todos Medical Supports Long COVID Awareness Day
Mar. 15, 2023

Todos Medical Enters Into Moratorium on Conversions Agreement With Convertible Note Holders
Mar. 13, 2023

Todos Medical Initiates Validation Plan for PCR-based Avian Influenza A (H5N1, Bird Flu) Test at CLIA/CAP Testing Lab Provista Diagnostics
Feb. 14, 2023

Todos Medical to Present at the RHK 2022 Disruptive Growth Conference
Dec. 06, 2022

Todos Medical’s 3CL Pharma Awarded Oral and Poster Presentations at World Antiviral Congress 2022
Nov. 29, 2022

Todos Medical to Attend World Antiviral Congress
Nov. 22, 2022

Todos Medical Enters Into Exclusive Worldwide Automated Retail Supply Agreement With Smart Automated Retail Network
Nov. 16, 2022

Todos Medical Terminates Tollovid™ Products License & Distribution Agreement with T-Cell Protect Hellas S.A.
Nov. 10, 2022

Todos Medical CLIA/CAP Lab Provista Submits Emergency Use Authorization Application for MonkeyPox PCR Test to US FDA
Oct. 14, 2022

Todos Medical Announces Successful Pilot Launch of Suite of PCR Testing Services by CLIA/CAP Lab Provista Diagnostics
Oct. 06, 2022

Todos Medical Receives Two Notices of Allowance from USPTO for AI-Based TBIA Pan-Cancer Blood Diagnostics Platform
Sep. 30, 2022

Todos Medical Announces USPTO Trademark Notice of Allowance for 3CL Protease Biomarker Diagnostics TolloTest™
Sep. 27, 2022

Todos Medical Enters Into $50M Contract to Supply Tollovid™ and CBD Products to Retail Distributor Company Nerd Hemp
Sep. 22, 2022

Todos Medical Announces NFL Hall of Famer Michael Irvin as Tollovid™ Sports Ambassador for #TolloUp Campaign
Sep. 16, 2022

Todos Medical Announces Preprint of Long COVID Case Study Participant with Confirmed Microclot and Hyperactivated Platelets who Benefitted from Tollovid
Sep. 15, 2022

Todos Medical & The Alchemist’s Kitchen to Host “Long COVID: An Integrated Approach” Event Benefitting Survivor Corps
Sep. 13, 2022

Todos Medical’s 3CL Protease Inhibitor Supplement Tollovid™ Featured in Wellness Magazine
Sep. 13, 2022

Todos Medical Partner NLC Pharma Assigns IP for Tollovir™, Tollovid™, and TolloTest™ into JV 3CL Pharma
Sep. 12, 2022

Todos Medical CEO Discusses Long COVID Economic Impact with Moneta Advisory Managing Partner Marc LoPresti
Sep. 09, 2022

Todos Medical Announce Kingcarlx as Brand Ambassador for the Tollovid #TolloUp Lifestyle Campaign
Sep. 02, 2022

Todos Medical Establishes Botanical Supplement Manufacturing Capabilities to Support Tollovid Global Expansion and Initiates CBD-A Production
Aug. 31, 2022

Todos Medical Expands COVID Onsite School Sample Collection to Include MonkeyPox Testing
Aug. 29, 2022

Todos Medical Announces Saliva-Only MonkeyPox Testing at CLIA/CAP Clinical Lab Provista Diagnostics
Aug. 26, 2022

Todos Medical Enrolls Female Long COVID Patient Unable to Secure Testing While Symptomatic for MonkeyPox into Provista Diagnostics Case Study Series
Aug. 25, 2022

Todos Medical Initiates MonkeyPox Diagnostic Case Studies After Being Approached by 4 Patients, Including 3 Women
Aug. 23, 2022

Todos Medical Announces Commercialization of Lesion and Saliva-Based MonkeyPox PCR Testing
Aug. 22, 2022

Todos Medical Announces Preprint of Data from First 100 Participants in IRB-waived Market Research Study of Supplementation with Tollovid in Long COVID
Aug. 19, 2022

Todos Medical Reports Pre-Print of Publication Detailing Tollovid Supplementation Following COVID-19 mRNA Vaccination in Long COVID
Aug. 15, 2022

Todos Medical Completes Trial Design for Tollovid™ Long COVID Clinical Study in Adults
Aug. 11, 2022

Todos Medical Announces PCR Validation of Wound and Respiratory Pathogen Panels at CLIA/CAP Lab Provista Diagnostics
Aug. 10, 2022

Todos Medical Announces First Two Contracts for PCR-based MonkeyPox Testing at CLIA/CAP Clinical Testing Laboratory Provista Diagnostics
Aug. 08, 2022

Todos Medical Announces First Long COVID Clinic Laboratory Services Agreement for Long COVID Panel Biomarker Partnership with Amerimmune Diagnostics
Aug. 05, 2022

Todos Medical Initiates Validation Plan for PCR-based MonkeyPox Test at CLIA/CAP Clinical Testing Laboratory Provista Diagnostics
Aug. 03, 2022

Todos Medical Announces Preprint of Acute COVID-19 Paxlovid Rebound Rescued by Tollovid
Aug. 01, 2022

Todos Medical Partners with Amerimmune Diagnostics on Long COVID Biomarker Panel
Jul. 28, 2022

Todos Medical Announces Preprint of Chronic Long COVID Case Study #8 of Paxlovid® Treatment Followed by Tollovid™ Dietary Supplementation
Jul. 22, 2022

Todos Medical Reports Case Study #7 in Acute and Long COVID
Jul. 12, 2022

Todos Medical Announces Positive Biomarker Data from Phase 2 Trial of Tollovir in Hospitalized COVID-19 Patients
Jun. 30, 2022

Todos Medical Releases Preliminary Data From IRB-Waived Tollovid® Market Research Study in Acute and Long COVID
Jun. 23, 2022

Todos Medical Retains Moneta Advisory Partners as Strategic Advisors for National Exchange Listing and 3CL Pharma Spinoff
Jun. 21, 2022

Todos Medical Completes Validation of 27 Pathogen UTI PCR Panel at Its CLIA/CAP Laboratory Provista Diagnostics
Jun. 13, 2022

Todos Medical Reports Day 45 Update for Case Study #6
Jun. 10, 2022

Todos Medical Reports Day 28 Update for Case Study #5 with Erectile Dysfunction
Jun. 07, 2022

Todos Medical Announces Enrollment Complete for Confirmatory Cohort of LymPro Alzheimer’s Blood Test Clinical Validation Trial vs. Amyloid PET
Jun. 03, 2022

Todos Medical Reports Day 26 Update For Case Study #4
Jun. 01, 2022

Todos Medical to Present Final Data from the Tollovir Phase 2 Clinical Trial in Hospitalized COVID-19 Patients at the Personalized Medicine World Conference
May 27, 2022

Todos Medical Reports Day 14 Update from Ongoing 30-Day Case Study of Paxlovid Rebound Patient
May 06, 2022

Todos Medical Receives New FDA Certificate of Free Sale for Tollovid® Max Strength Including 5 Day Dosing, 30 Day Dosing and 3CL Protease (3CLpro, Mpro, Nsp5) Inhibitor Claim
May 02, 2022

Todos Medical Initiates IRB-Waived Tollovid Market Research Study and Announces 50% Price Reduction Until May 30th, 2022
Apr. 27, 2022

Todos Medical Appoints Philippe Goix as Chief Commercial Officer for Provista Diagnostics
Apr. 21, 2022

Todos Medical Reports 2nd Long COVID Case Study and Launches Website for Physicians and Pediatricians to Indicate Interest in Participating in Tollovid Long COVID Clinical Study
Apr. 20, 2022

Todos Medical Targets Athlete Support with Informed Sport Certification for Tollovid by LGC Group
Apr. 19, 2022

Todos Medical Applauds White House Initiative on Long COVID and Announces New Tollovid® US FDA Certificate of Free Sale with Daily and Acute Dosing on the Label
Apr. 06, 2022

Todos Medical Announces Positive 3CL Protease Inhibition In Vitro Data Against BA.1 and BA.2 Omicron SARS-CoV-2 Variants
Apr. 04, 2022

Todos Medical Reports Case Study of Patient with Long COVID
Mar. 31, 2022

Billy Blanks® Endorses Todos Medical’s Line of Tollovid® Products
Mar. 28, 2022

Todos Medical Completes Acquisition of Key Assets and Intellectual Property from NLC Pharma
Mar. 16, 2022

Todos Medical Appoints Greg Meiselbach as Vice President of Government Affairs
Mar. 08, 2022

Todos Medical and NLC Pharma Announce Primary and Secondary Endpoints Met in NLC-V-01 Phase 2 Clinical Trial of Oral Antiviral 3CL Protease Inhibitor Tollovir™ in the Treatment of Hospitalized COVID-19 Patients
Jan. 27, 2022

Todos Medical Announces Data Lock in Tollovir Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients
Jan. 24, 2022

Pepperdine University Hosts the 22nd Annual Celebrity Flag Football Challenge®, Presented by Todos Medical’s Tollovid®
Jan. 19, 2022

Todos Medical Releases Videos of Recent CEO Interviews with Fox Business, NewsMax and Black News Channel on COVID Testing & Treatment Strategies
Jan. 18, 2022

Todos Medical to Announce Topline Results from Tollovir™ Phase 2 Clinical Trial from the Treatment of Hospitalized COVID-19 Patients on January 27th, 2022
Jan. 12, 2022

Todos Medical CEO to Appear on Fox Business to Talk COVID Testing & Tollovir on Tuesday, January 11, 2022 and is Presenting at Biotech Showcase 2022
Jan. 10, 2022

Todos Medical Records Record Weekly COVID PCR Testing Volumes at Provista
Dec. 27, 2021

Todos Medical CEO to Appear on Yahoo Finance Live! at 12:10PM EST with Akiko Fujita to Talk Pfizer’s Paxlovid Approval, Tollovir™ Phase 2 & COVID Testing
Dec. 23, 2021

Todos Medical Announces New cPass Neutralizing Antibody Testing Reference Lab Agreement for CLIA/CAP Lab Provista with Physician Group in 40 States
Dec. 22, 2021

Todos Medical Appoints Valentino Smith, MBA as Vice President of Marketing
Dec. 20, 2021

Todos Medical Announces “Test & Tollovid®” Holiday Package for Atlanta Area at Provista Diagnostics
Dec. 17, 2021

Todos Medical to Host Key Opinion Leader Webinar Entitled Tollovir™: a Potential Treatment for Covid-19
Dec. 16, 2021

Todos Medical Enters 90-Day Extension of Agreement with Convertible Note Holders on Moratorium on Conversions of Convertible Notes
Dec. 13, 2021

Todos Medical Interview and Presentation on Benzinga's All Access Conference Live December 14th at 10:20 AM EST
Dec. 10, 2021

Todos Medical Announces 2 New COVID-19 PCR Testing Reference Lab Agreements for CLIA/CAP Lab Provista Diagnostics
Dec. 07, 2021

CEOs Presenting at the Emerging Growth Conference on December 8; Register Now
Dec. 07, 2021

Todos Medical to Present at Upcoming Emerging Growth Conference
Dec. 06, 2021

Todos Medical Announces All 31 Patients Enrolled to Date in Tollovir® Phase 2 Clinical Trial in Hospitalized COVID-19 Patients Have Completed Study Participation
Dec. 02, 2021

Todos Medical Confirms SARS-CoV-2 PCR Test Kits Used at CLIA/CAP Lab Provista Diagnostics Detect Omicron Variant
Nov. 30, 2021

Todos Medical Enters into Binding Agreement to Acquire All 3CL Protease Biology-Related Assets and Intellectual Property from NLC Pharma
Nov. 29, 2021

Todos Medical Receives Purchase Order for 50,000 Bottles of Tollovid Daily from Its European Distribution Partner T-Cell Protect Hellas S.A for Initial Market Launch in Greece
Nov. 22, 2021

Todos Medical Announces Completion of Enrollment for COVID-19 Oral Antiviral 3CLPro (Mpro) Inhibitor Tollovir Phase 2 Clinical Trial Interim Analysis in Severe and Critical Hospitalized Patients
Nov. 19, 2021

Todos Medical Announces Tollovid® Products Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. Covering 30 Countries in Europe
Nov. 18, 2021

Todos Medical Announces Addition of Semi-Quantitative Titer Claims to the Emergency Use Authorization for the cPass Neutralizing Antibody Test
Nov. 17, 2021

Todos Medical’s Provista Laboratory to Boost Top Line Through New Atlanta-based Reference Lab Agreement for COVID PCR, cPass Neutralizing Antibody & Respiratory Pathogen Panel Tests
Nov. 16, 2021

Todos Medical Reports Third Quarter 2021 Business and Financial Results
Nov. 15, 2021

Todos Medical Sees Significant Ramp Up in COVID PCR Testing Volume at Its Provista CLIA/CAP Lab with New Automation in Place
Nov. 02, 2021

Todos Medical Announces 2nd Clinical Trial Site for Tollovir Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients
Nov. 01, 2021

Todos Medical Announces Publication in Nature Neuroscience That Describes the Main Protease (3CL Protease) Causes Microvascular Brain Pathology
Oct. 25, 2021

Todos Medical Announces Publication in Journal of Clinical Virology Highlighting Clinical Utility of cPass Semi-Quantitative Neutralizing Antibody Test in SARS-CoV-2 Risk Assessment Post-Vaccination or Recovery from Infection
Oct. 21, 2021

Todos Medical to Conduct Webinar Highlighting the cPass SARS-COV-2 Neutralizing Antibody Test for AMDA, The Society for Post-Acute and Long-Term Care Medicine, on October 22, 2021 at 12:00 PM EDT
Oct. 14, 2021

Todos Medical Announces Positive Data in Hospitalized and Outpatient Setting for TolloTest™, a Novel SARS-CoV-2 3CL Protease Biomarker Assay
Oct. 06, 2021

Todos Medical Provides Update on COVID-19 Oral Antiviral 3CL Protease (Main Protease) Inhibitor Tollovir Clinical Development Program in Light of Molnupiravir Clinical Trial Data from Merck
Oct. 04, 2021

Todos Medical Announces Positive Observational Trial Results for Oral Antiviral 3CL Protease (MPro) Inhibitor Tollovir®
Sep. 30, 2021

Todos Medical Receives Approval by Amazon to Sell Immune Supplements Tollovid® & Tollovid Daily™
Sep. 27, 2021

Todos Medical Reports Second Quarter 2021 Financial Results
Fri, Sep. 24, 2021

UPDATE: Todos Medical Announces 90-Day Moratorium on Conversions of Convertible Notes and Lockup of Common Stock Sales with Convertible Note Holders
Sep. 24, 2021

Todos Medical Launches Tollovid Daily™ via Subscription at MyTollovid.com
Sep. 23, 2021

Todos Medical Receives Trademark Notice of Allowance from USPTO for Its 3CL Protease Inhibitor Oral Antiviral Drug Candidate Tollovir™
Sep. 20, 2021

Todos Medical Now Accepting Cryptocurrency for the Purchase of Tollovid® and Tollovid Daily™ Through Coinbase Commerce
Sep. 17, 2021

Todos Medical Announces 90-Day Moratorium on Conversions of Convertible Notes and Lockup of Common Stock Sales with Convertible Note Holders
Sep. 15, 2021

Todos Medical’s CLIA/CAP Lab Provista Completes Validation of Combination COVID, Influenza A & B, RSV & hMPV Respiratory Panel Test
Sep. 01, 2021

Todos Medical’s CLIA/CAP Lab Provista Completes Validation of High-Capacity SARS-CoV-2 Variant Testing Service Capable of Identifying Known Variants
Aug. 26, 2021

Todos Medical’s CLIA/CAP Lab Provista Enters Into Reference Lab Agreement with Meadowlands Diagnostics to Provide cPass Neutralizing Antibody Blood Testing for Quantifying and Monitoring Key COVID-19 Immunity Biomarkers
Aug. 24, 2021

Todos Medical Completes Validation of cPass Neutralizing Antibody Blood Test at Provista Diagnostics to Quantify and Monitor Key Biomarkers of COVID-19 Immunity
Aug. 23, 2021

Todos Medical CEO to Appear on Fox Business Network Varney & Company Today at 11:40am to Discuss the Company’s Launch of cPass Neutralizing Antibody Testing for Monitoring COVID-19 Immunity
Aug. 23, 2021

Update: Todos Medical Receives Trademark Notice of Allowance from USPTO for Its 3CL Protease Inhibitor Dietary Supplement Tollovid™
Aug. 05, 2021

Todos Medical Receipt Notice of Allowance from USPTO for 3CL Protease Inhibitor Dietary Supplement Tollovid™
Aug. 05, 2021

Todos Medical Makes Final Payment to Close Provista Diagnostics Acquisition
Aug. 02, 2021

Todos Medical Retains CRO for COVID-19 Outpatient and Inpatient Phase 2/3 Clinical Trials for Oral Antiviral 3CL Protease Inhibitor Tollovir
Jul. 28, 2021

Todos Medical Receives New FDA Certificate of Free Sale for Tollovid Daily™ Including 3CL Protease Inhibitor Claim
Jul. 22, 2021

Todos Medical to Launch EUA Authorized cPass SARS-CoV-2 Neutralizing Antibody Kit Through Agreement with Fosun Pharma
Jul. 19, 2021

Todos Medical Appoints Ilanit Halperin, CPA as Corporate Controller
Jul. 07, 2021

Todos Medical Receives FDA Certificate of Free Sale for New 5-Day Tollovid Dosing Regimen
May 04, 2021

Todos Medical Launches Phase 2 Clinical Trial of Its Antiviral 3CL Protease Inhibitor NLC-V-01 (Tollovir) in Hospitalized COVID-19 Patients
Apr. 19, 2021

Todos Medical Receives Notice of Allowance from European Patent Office for Patent Application Covering Diagnosis of Cancer Using Proprietary Artificial Intelligence TBIA Immune Profiling Platform
Apr. 08, 2021

Todos Medical Completes Automation Equipment Installation and Training for Meadowlands Diagnostics
Apr. 01, 2021

Todos Medical Enters Into Distribution Partnership with Osang Healthcare for the GeneFinder Plus™ COVID-19 Plus RealAMP Kit in the United States
Mar. 30, 2021

Todos Medical Completes Automation Equipment Installation and Training for a Laboratory Client in Brooklyn, NY
Mar. 29, 2021

Todos Medical Enters Into Automation and Reagent Supply Agreement with MAJL Diagnostics
Mar. 23, 2021

Todos Medical Announces $7.2M in Sales for February 2021, a 38% Month Over Month Increase From Sales of $5.2M in January 2021
Mar. 12, 2021

Todos Medical Applauds Senate and House Passage of the American Recovery Act
Mar. 11, 2021

Todos Medical Announces Strategic Investment by Yozma Group Korea
Jan. 25, 2021

Todos Medical Announces $4.8 Million in Sales for December 2020, a 50% Month Over Month Increase in Sales from November 2020
Jan. 11, 2021

Todos Medical Announces Agreement to Supply Natural Wellness Clinics with COVID-19 Testing Products to Support Initiatives in the Commonwealth of Kentucky
Dec. 23, 2020

Aditxt Signs Distribution Agreement with Todos Medical Ltd. For AditxtScore™ for COVID-19 Immune Monitoring Service
Dec. 14, 2020

Todos Medical Announces Commercial Launch of Proprietary 3CL Protease Inhibitor Dietary Supplement Tollovid™ at The Alchemist’s Kitchen
Dec. 07, 2020

Todos Medical Announces $3.2 Million in Sales for November 2020, a 269% Increase Sequential Month over Month Sales Growth from October 2020
Dec. 02, 2020

Todos Medical Provides Strategic Outlook
Dec. 01, 2020

Todos Medical Completes Installation of Lab Automation Equipment at Wisconsin Lab Client to Support COVID-19 PCR Testing
Nov. 24, 2020

Todos Medical Announces Positive In Vitro Data for Tollovid™ Confirming 3CL Protease Inhibition Mechanism of Action
Nov. 20, 2020

Todos Medical Announces Positive Initial Clinical Proof-of-Concept Data for a Rapid SARS-CoV-2 3CL Protease Detection Assay
Nov. 18, 2020

Todos Medical Announces Clinical Validation and National CLIA Certification for MOTO+PARA Mobile High Complexity Labs
Nov. 17, 2020

Todos Medical Announces $867,000 in Sales for October 2020
Nov. 12, 2020

Todos Medical Trademarks Tollovid for Dietary Supplement NLC-001 and Enters Into Private Label & Distribution Agreement With The Alchemists Kitchen
Oct. 29, 2020

Todos Medical Announces Instrument Validation Complete at MOTO+PARA Mobile Lab
Oct. 26, 2020

Todos Medical Announces Distribution Agreement with Adial Pharmaceuticals to Market the FDA, EUA Authorized, Assure/FaStep Point-of-Care Covid-19 Antibody Tests
Oct. 22, 2020

Todos Medical Receives Notices of Allowance From the European Patent Office Covering Use of TBIA Cancer Platform to Detect Benign Colon Cancer
Oct. 20, 2020

Todos Medical Reports $2.0 Million in Revenue for the Third Quarter of 2020
Oct. 13, 2020

Todos Medical Enters into Exclusive COVID-19 Testing Supply Agreement with MOTO+PARA’s National Mobile CLIA Lab Partner Integrated Health
Oct. 07, 2020

Todos Medical Enters into Exclusive Branding and Distribution Agreement with Melbourne Biotech for 96 and 384 Well RT-PCR Machines in the United States
Sep. 30, 2020

Todos Medical Enters Into COVID-19 PCR Testing Implementation and Equipment Financing Partnership with AID Genomics
Sep. 25, 2020

Todos Medical Expands Existing Contract for COVID-19 PCR Testing Equipment & Supplies with Wisconsin-based Laboratory to $47.5 Million
Sep. 22, 2020

Todos Medical CEO Releases Letter to Shareholders
Sep. 18, 2020

3CL Protease Inhibitor NLC-001 Added to COVID-19-focused Joint Venture Between Todos Medical and NLC Pharma
Sep. 17, 2020

Todos Medical Expands Partnership with Care G.B. Plus for Proprietary TBIA Cancer Tests to Include Europe, Israel and Africa
Sep. 16, 2020

Todos Medical Announces Commercial Launch of Todos Branded COVID-19 qPCR Test Kits in the United States
Sep. 11, 2020

Todos Medical Announces August Sales of $1,190,000, Up 100% Compared with July
Sep. 03, 2020

Todos Medical Enters Into Partnership With Pangea for COVID-19 Testing and Contact Tracing
Sep. 02, 2020

Todos Medical Announces $23,760,000 Contract for COVID-19 PCR Testing Equipment & Supplies With Wisconsin-based Laboratory
Aug. 31, 2020

Todos Medical to Present at The LD 500 Virtual Conference
Aug. 31, 2020

Todos Medical Announces $4,500,000 Contract for COVID-19 PCR Testing Equipment & Supplies with New York-based Laboratory
Aug. 27, 2020

Todos Medical Appoints Marsha Fontanive as VP of Sales and Chris Gross as VP of Sales Operations
Aug. 25, 2020

Todos Medical Announces $1.2 Million Contract for COVID-19 PCR Testing Equipment & Supplies with Texas-based Laboratory
Aug. 24, 2020

Todos Medical Announces $6,000,000 Contract for COVID-19 PCR Testing Equipment & Supplies with New York-based Laboratory
Aug. 21, 2020

Todos Medical Announces Positive Proof-of-Concept Data for Novel 10-Minute Point-of-Care Saliva-based Test Detecting Active SARS-CoV-2 Infection
Aug. 17, 2020

Todos Medical Acquires Distribution Rights to SARS-CoV-2 Rapid Point-of-Care Antigen Test and Rapid Point-of-Care PCR Test
Aug. 14, 2020

Todos Medical Announces July Sales of COVID-19 Tests
Aug. 07, 2020

Todos Medical Announces Common Stock Purchase Agreement with Lincoln Park Capital Fund, LLC
Aug. 06, 2020

Todos Medical Appoints Dr. Jorge Leon as Consulting Chief Medical and Scientific Officer of Infectious Disease and Oncology
Aug. 04, 2020

Pathnova Laboratories (PATHNOVA) Enters into Partnership to Commercialize Todos Medicals COVID-19 and Breast Cancer Tests in Singapore
Aug. 03, 2020

Todos Medical Completes Acquisition of Breakthrough Diagnostics, Gains Full Rights to the Alzheimer’s Blood Diagnostic LymPro™ Test from Amarantus
Jul. 28, 2020

Todos Medical Announces SARS-nCoV-19 Testing Kit Contract with NJ-Based Best Supply Clinical Laboratory
Jul. 27, 2020

Todos Medical Expands Management Team and Advisory Board
Jul. 20, 2020

Todos Medical Announces ANVISA Authorization in Brazil for 3D Med qPCR Kits and ANDis Extraction S
Jul. 16, 2020

Todos Medical Releases Letter to Shareholders
Feb 07, 2020 9:15am EST

Todos Medical Enters into Exclusive Option Agreement to Acquire Provista Diagnostics and Announces Management Changes
Jan 09, 2020 8:00am EST

Todos To Present At Upcoming 12th Annual LD Micro Main Event
Dec 06, 2019 7:29am EST

Todos and Amarantus JV Announces Full Enrollment for Clinical Trial of LymPro Alzheimer’s Blood Test Relationship with Amyloid PET
Nov 14, 2019 11:02am EST

Todos Medical to Present at Dawson James Small Cap Growth Conference
Oct 24, 2019 9:25am EDT

Todos Medical and Orot+ Announce First Patient Enrolled in Pre-Commercial Launch Preparations of TM-B1 and TM-B2 Breast Cancer Blood Screening Tests in Europe
Sep 24, 2019 9:14am EDT

Todos Medical Signs Binding Term Sheet with HWH World for Network Marketing of Blood Tests for the Early Detection of Breast Cancer
Sep 13, 2019 7:30am EDT

Todos Medical Enters into MOU to Expand Existing Early Detection Breast Cancer Blood Test Distribution Partnership with Orot+ into Japan
Sep 03, 2019 1:29pm EDT

Todos Medical Appoints Dr. Jorge Leon as Medical Advisor
Aug 06, 2019 7:00am EDT

Todos Medical Announces Positive Alzheimer's Biomarker Clinical Data from LymPro vs. Amyloid PET Interim Analysis
Jul 15, 2019 7:00am EDT

Todos Medical CEO Presented Corporate Update And Roadmap at The LD Micro Conference
Jun 17, 2019 8:30am EDT

Todos Medical Announces Positive Clinical Trial Data for Breast Cancer Blood Test TM-B1 in Dense Breasts
Jun 03, 2019 8:00am EDT

Todos Medical Exercises Option to Acquire Remaining 80.01% of Breakthrough Diagnostics from Amarantus After Review of Alzheimer's Blood Test Data
May 28, 2019 8:57am EDT

Todos Medical Receives Approval from Israeli Ministry of Health (AMAR) to Market and Sell its Breast Cancer Screens in Israel
May 23, 2019 8:00am EDT

Todos Medical Enters Exclusive Distribution Agreement with Care G.B. Plus, Ltd. for its Breast Cancer Screening Tests in Israel
May 21, 2019 8:00am EDT

Todos Medical Announces Voting Results from 2019 Annual Shareholder Meeting
May 03, 2019 8:52am EDT

Todos Medical Receives Notice of Allowance from the USPTO Covering the Early Diagnosis of Lung Cancer Using the Todos Biochemical Infrared Analysis (TBIA)
May 01, 2019 8:00am EDT

Todos Medical Enters Into Definitive Agreement With Orot+ for Exclusive Distribution Rights of its Breast Cancer Screening Tests in 2 European Countries
Apr 15, 2019 8:00am EDT

Todos and Amarantus Announce Completion of LymPro PET 1 Study by Leipzig University for Alzheimer’s Blood Diagnostic LymPro Test 2.0
Apr 08, 2019 7:30am EDT

Todos Medical to Present at Two Upcoming Investor Conferences
Mar 28, 2019 8:00am EDT

Todos Medical Appoints Dr. Colin Bier to Its Board of Directors
Mar 27, 2019 8:00am EDT

Todos Medical Raises $1,350,500 In Funding and Finalizes Joint Venture Agreement with Amarantus Bioscience
Feb 28, 2019 9:30am EST

Todos Medical Presents Encouraging Scientific Abstract at the San Antonio Breast Cancer Symposium (SABCS)
Dec 06, 2018 4:00pm EST

Todos Medical Enters into Joint Venture Agreement with Amarantus to develop Alzheimer’s Blood Diagnostic LymPro Test 2.0
Dec 03, 2018 8:30am EST

Todos Medical to Present Scientific Abstract at the Upcoming San Antonio Breast Cancer Symposium (SABCS)
Nov 29, 2018 8:30am EST

Todos Medical, Ltd. Announces Additional Patent Issuance Covering the Use of IR Spectrum of Blood Plasma For Indicating the Presence of Breast Cancer
Oct 17, 2018 8:30am EDT

Todos Medical, Ltd. Signs Non-Binding Memorandum of Understanding with Orot+ for Distribution Rights of its Breast Cancer Screening Tests in Romania and Austria
Sep 13, 2018 8:30am EDT

Todos Medical, Ltd. Appoints Herman Weiss, MD MBA as New Chief Executive Officer
Jul 31, 2018 4:03pm EDT

Todos Medical reports on results of clinical trials for its blood test for breast cancer screening (TM - B1) conducted at Kaplan Hospital in Rehovot, Israel
Mar 22, 2018 8:00am EDT

Todos Medical initiates clinical trial of its blood test for breast cancer in Kaplan Hospital, Rehovot, Israel for subjects undergoing breast cancer screening
Mar 05, 2018 8:00am EST

U.S. Patent and Trademark Office has granted to Todos Medical two additional patents
Feb 12, 2018 8:00am EST

Mr. David Ben Naim, CPA, MBA Joins Todos Medical as Chief Financial Officer
Feb 06, 2018 8:00am EST

Todos Medical Appoints Dr. Meir Silver as Vice President of Clinical Research and Regulatory Affairs
Aug 29, 2017 8:30am EDT

SMH - no need to look any further than the TOMDF Boiler Room Pump Boys



and we all know who those shills touts and dolts are...!

MOO sham

[1maga1]

Holy crap!!! Just shocked at how far this dropped lol

[redspeed]

TOMDF will surprise...

even french maids and fake Todos Stock Analysts

[velcro]

Can't believe Joe Forkey sold. This bugger is going to move (LOL)

[JPetroInc]

TOMDF printing $0.000001 - yes folks that 5 zero's

how's that going to help General Maximus Decimus Meridious - or you...?



you can change a moniker - but the person behind it always remains the same

SMH - can't make this stuff up

MOO dookie

[redspeed]

⭐⭐⭐⭐⭐ Star Post

Does the Todos Stock Analyst gets his investment ideas from reading Harlequin romance novels since he's been referring to them for over 10 years and posted many times about them?

Yeah it's odd that the things he accuses others of doing, he's actually did and still doing them on GCs stock and others. No one that didn't block him yet takes anything he says seriously as he's been wrong on his stock picks for over a dozen years. That's why he's referred to as the Laughing-Stock Analyst.

[JPetroInc]

strong like bullshite more like it ... down -99% in 1 day

Printing $0.000001
52 Week Range
$0.000001 - $0.004

Holy bat-cack Batman...!



all the shill, tout, and dolt TOMDF Boiler Room Pumper Boy's sure helped bigley this turd - eh...?

of course, along with the $720k/yr. salaried CEO twice failed Stanford University "Financial Engineer" hack

not including CEO travel, auto, speaking engagement's, retirement bene's, options, etc etc etc

but hey, where did (+/-) $138-Mil. go in just 5 years time - do we have audited books to tell the tail...?

SMH - you simply can't make this stuff up folks



oh and they don't like me - ha...!

MOO - TOMDF death knell

[theswordman]

Every once in a while--there is 1 of those "mic drop" posts
Some would say 5 STAR

KUDOS for that

[velcro]

Strong like Bull____.

[redspeed]

Todos strong like Bull

[JPetroInc]

God's Devine supernatural abundance & Grace to you & yours this 2024

All the best,

[Gainzzz]

Lol sure…

Godspeed, my man.

[JPetroInc]

you got it all wrong partner

but hey, good fortunes to you in your next $50k investment in Gerald Commissiong

I understand he's looking a 2nd chance - or would that be his 3rd...?



MOO sad

[Gainzzz]

Proof is you’re still on this board daily bantering nonsense to two people because GC takes up 99% of your mental real estate. He took all your money. No sane person who hasn’t lost his life to a man does and says the things you do. That’s proof. You’re insanely vengeful because GC lost all your money. Simple as that.

I Just came to this board for the first time in months for fun tonight. I lost about 50k in todos. Haven’t spent more than the time with my cpa deducting loses thinking about it. So about 3 minutes. Because that’s what normal people who aren’t prisoners of a man who lost all their money do.

You should post less and go work your butt off for your family. They deserve it. Just my .00001 cents.

[theswordman]

SUN NITE COVID UPDATE
BNO News @BNOFeed
Weekly U.S. COVID update:

- New cases: 146,588 est.
- Average: 181,978 (-22K)
- States reporting: 50/50
- In hospital: 14,785 (-1K)
- In ICU: 1,845 (+28)
- New deaths: 1,658
- Average: 1,672 (-161)

BNO ANALYSIS OF DATA:
Cases and hospitalizations remain elevated across the U.S. but have steadily declined during the past few weeks. Deaths remain elevated from this winter's peak.

During the past week, 15,141 Americans were hospitalized with COVID, down 13% from the week before. Close to 15,000 people are currently hospitalized.

So far this year, more than 2.5 million cases of COVID have been reported in the U.S., causing 209,000 hospitalizations and nearly 21,000 deaths.

[JPetroInc]

source...?

of course you can't provide one - because you make things up Mista Redspudda

including all the hype you and your ilk made-up about Tolloup Buttercup 9 horsie TOMDF

oh, did you state it was too late to provide your Tolloup testimonial for Todos Medical's CrowdFunding Launch...?



sorry Sporto - you are seriously delusional...!

SMH - if it weren't so pathetic, it would be funnier than hell...

MOO putz

[redspeed]

I hear JWP Inc. stock analyst that follows Todos is flat broke. Got so caught up in gambling the next egg on JUNK stocks, he forget to actually invest in real securities. One can make a LOT of money doing the opposite of the JWP Inc. stock analyst that follows Todos.